Relationship Between Glycemic Indices and eGFR Values Among Type 2 Diabetes Mellitus Individuals With Chronic Kidney Disease Across Various Progression Stages

Document Type

Article

Publication Title

Clinical Medicine Insights Endocrinology and Diabetes

Abstract

Background: T2DM is a significant contributor to hypoglycemia, mortality, CVD, as well as a leading cause of CKD. Understanding and managing glycosylation discrepancies in T2DM patients with CKD is critical because they are important in disease causation and progression. Aim of this correlation study was to investigate the accuracy of HbA1c and fructosamine as predictors of declining renal function in the context of T2DM, by comparing and evaluating their relationships with eGFR across stages 1 to 5. Methods: We included individuals with T2DM aged over 18 years, diagnosed per ADA guidelines, and potential CKD (stage 1-5) in T2DM patients. Outcomes involved measuring HbA1c and fructosamine levels of all participants. Results: We recruited 424 participants from Department of Medicine, Kasturba Medical College, MAHE, Manipal on OPD & IPD. For patient in CKD stage 1 to 4, a weak positive correlation was noticed between HbA1c and eGFR. For patient in CKD stage 1 to 4, a weak negative correlation was found between eGFR and Fructosamine. Conclusion: For determining long-term blood sugar management and forecasting the course of kidney disease in individuals with type 2 diabetes, the HbA1c test remains a crucial and dependable tool. However, it might occasionally be more difficult to interpret HbA1c values in later stages of CKD. Fructosamine, a shorter-term blood sugar indicator, can offer useful further information in certain situations. We advise combining the 2 tests for optimal diabetes management: fructosamine for prompt medication modifications, particularly in advanced CKD and HbA1c for long term trends and risk assessments.

DOI

10.1177/11795514251362516

Publication Date

1-1-2025

This document is currently not available here.

Share

COinS